Connect Biopharmaceuticals Raises $115M Series C Round

Suzhou Connect Biopharmaceuticals, Ltd. has announced the completion of a US$115 million series C round of financing. This round of financing was led by RA Capital Management. Lilly Asia Ventures, Boxer Capital and HBM Healthcare Investments also participated in the investment. Existing investment shareholder Qiming Venture Partners continued to join the latest investment.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in